DGX · Quest Diagnostics Q2 FY2026 earnings call record财报电话会记录

“Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.”

“In the quarter, we grew revenues by over 10%, driven by broad clinical demand from physicians, hospitals, and consumers, and increased volume from our collaborations with Corewell Health and Fresenius Medical Care.”

“We are also using advanced technologies to make it easier for our customers to engage with us and draw greater insights from our lab data.”

“Through these deep relationships, we have created a strong pipeline of potential collaborations and acquisitions of hospital outreach, as well as independent labs.”

“Revenues for diagnostic information services were up 10.3% compared to the prior year, with 10.1% organic growth, reflecting strong growth in our physician, hospital, and consumer channels.”

“With our strong first-half performance and continued momentum, we are raising our full-year revenue and EPS estimates.”

“Cash from operations to be approximately $1.8 billion, and capital expenditures to be approximately $550 million.”

“Nova expenses are unchanged for the full year, but we anticipate increased spend in the H2 of the year compared to prior expectations.”

“Revenues increased by over 10%, almost all from organic revenues, while adjusted diluted EPS grew by over 19%.”

“I'm just curious what you're seeing across that channel right now, how those relationships are progressing, and just given some of the headwinds, whether it's reimbursement or otherwise across the hospital segment, I guess, are you seeing a building hospital deal pipeline, and how do some of those relationships work?”

“Lisa, just to reaffirm what Jim said, in terms of our guidance for the year, we're still assuming for the full year that there's a 30 basis point impact on revenue from the ACA exchange subsidy expiration.”

“A replay of the call may be accessed online at www.questdiagnostics.com/investor, or by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers.”